Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 76,3% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Bristol Myers BMY

BristolMyers realtidsdiagram

Insikter

Weekly Search
Weekly
Daily
date Stäng change Förändring (%) Öppna Hög Låg

Markets.com news

New Zealand dollar drops on unexpected dovish tone from RBNZ
Georgy Istigechev 2024 Jul 10, 10:00

Unexpected dovish tone from RBNZ drops New Zealand dollar

Forex Indices USD
Sterling steady as investors take in UK, French election results
Georgy Istigechev 2024 Jul 09, 10:15

Sterling steady near one-month high in wake of UK election

Forex Indices GBP USD EUR
BP shares fall on Q2 profit warning
Georgy Istigechev 2024 Jul 09, 10:00

BP shares drop over 4% on Q2 lower profit warning

Shares Indices Oil FTSE100
BP shares dip ahead of Powell Congress testimony
Neil Wilson 2024 Jul 09, 07:30

BP dips, Powell Congress speech ahead, records for Tokyo, NY

Shares Indices Forex Commodities

Info

Spread

0.35

Spread (%)

0.6284 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Tisdag

14:31 - 20:59

Måndag

14:31-20:59

Onsdag

14:31-20:59

Torsdag

14:31-20:59

Fredag

14:31-20:59

Resultaträkning

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

116782604288

Utelöpande aktier

2028179968

Rapportdatum (nästa)

2001-08-07

instr__dividend_date

2025-02-03

instr__ex_dividend_date

2025-01-03

instr__forward_annual_dividend_rate

2.48

instr__forward_annual_dividend_yield

0.0433

Vinst per aktie

-3.58

Utelöpande aktier

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot
Live Chat